Chemo-immunotherapy before surgery for triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new combination of chemotherapy and immunotherapy that avoids a class of drugs called anthracyclines, which can be hard on the heart. The goal is to shrink tumors before surgery for people with triple-negative or low-hormone-receptor breast cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with triple-negative or low hormone receptor breast cancer, stage II or III.
- Your tumor is larger than 1 cm, and you have not had chemotherapy, immunotherapy, or radiation for this cancer before.
- You are at least 18 years old and have a good overall health status (able to do daily activities).
- You are not able to take anthracycline chemotherapy, either due to heart risk, previous treatment, or personal choice after discussion with your doctor.
- You have adequate kidney, liver, and blood cell counts as determined by lab tests.
- You are willing to use highly effective birth control or are not able to become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of chemotherapy and immunotherapy given before surgery for triple-negative breast cancer. It aims to shrink the tumor and improve outcomes. The treatment is given intravenously.
This trial tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy (carboplatin + paclitaxel) before surgery can improve outcomes for people with early-stage triple-negative breast cancer. It aims to shrink the tumor and increase the chance of a complete response.
This trial tests whether a combination of chemotherapy drugs (nab-paclitaxel and carboplatin) plus an immunotherapy drug (PD1 inhibitor) given before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by using these treatments before the main surgery.
This trial tests a combination of an immunotherapy drug (pembrolizumab) plus two chemotherapy drugs (carboplatin and paclitaxel) given before surgery for people with early-stage, triple-negative breast cancer. The goal is to see if this treatment helps shrink or eliminate the tumor before it's removed.
This trial compares two different chemotherapy combinations given before surgery (neoadjuvant therapy) for people with triple-negative breast cancer. It looks to see which drug combination works better to control the cancer before and around the time of the operation.
This trial studies a short course of sintilimab (an immune treatment) added to standard chemotherapy drugs before surgery for triple-negative breast cancer. It may help shrink the tumor and improve outcomes by boosting the immune system while you receive treatment.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.